Patents by Inventor Uwe Rohr

Uwe Rohr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SIMULTANEOUS CO-TREATMENT OF PHYSICAL AND MENTAL SYMPTOMS RELATED TO SEVERE MENTAL DISORDERS BY A SPECIALLY FERMENTED SOY FORMULATION (FSWW08)
    Publication number: 20130034537
    Abstract: A method of treating severe mental diseases and related disorders or conditions includes administering to a patient in need thereof an effective amount of a composition including isoflavones and Bowman Birk Inhibitory Factor (BBIF). Preferably, the composition is a fermented soy composition. Preferably, one first diagnoses a patient with a particular mental disease or disorder, and then prescribes the composition as a treatment for the particular mental disease or disorder. A patient is preferably given daily a dosage of 3-10 mg of isoflavones and 5-10 Cl (chymotrypsin inhibitor) of BBIF per kg of body weight, more preferably a dosage of 5-9 mg of isoflavones and 5-10 CCl of BBIF per kg of body weight, and most preferably a dosage of 5-10 mg of isoflavones and 5-10 CCl of BBIF per kg of body weight. Treatment preferably lasts 7 days-14 days, or until all symptoms disappear.
    Type: Application
    Filed: December 8, 2011
    Publication date: February 7, 2013
    Inventors: Anca-Gabriela GOCAN, Uwe ROHR, Walter WAINRIGHT
  • Transdermal system for the administration of pharmacological compounds under pH-controlled conditions
    Patent number: 5462744
    Abstract: The invention relates to an improved transdermal administration of pharmacologically active compounds.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: October 31, 1995
    Assignee: Boehringer Ingelheim KG
    Inventors: Arun R. Gupte, Uwe Rohr, Bernd Zierenberg
  • Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
    Patent number: 5112842
    Abstract: The invention relates to the transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole or the (-)-enantiomer thereof and transdermal systems containing these active substances.
    Type: Grant
    Filed: November 8, 1990
    Date of Patent: May 12, 1992
    Assignee: Boehringer Ingelheim KG
    Inventors: Bernd Zierenberg, Michael Herschel, Uwe Rohr